AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.

Abstract

Numerous hypotheses including amyloid cascade, cholinergic, and oxidative have been proposed for pathogenesis of Alzheimer's disease (AD). The data suggest that advanced glycation end products (AGEs) and its receptor RAGE (receptor for AGE) are involved in the pathogenesis of AD. AGE-RAGE stress, defined as a balance between stressors (AGE, RAGE) and anti-stressors (sRAGE, AGE degraders) in favor of stressors, has been implicated in pathogenesis of diseases. AGE and its interaction with RAGE-mediated increase in the reactive oxygen species (ROS) damage brain because of its increased vulnerability to ROS. AGE and ROS increase the synthesis of amyloid β (Aβ) leading to deposition of Aβ and phosphorylation of tau, culminating in formation of plaques and neurofibrillary tangles. ROS increase the synthesis of Aβ, high-mobility group box 1(HMGB1), and S100 that interacts with RAGE to produce additional ROS resulting in enhancement of AD pathology. Elevation of ROS precedes the Aβ plaques formation. Because of involvement of AGE and RAGE in AD pathology, the treatment should be targeted at lowering AGE levels through reduction in consumption and formation of AGE, and lowering expression of RAGE, blocking of RAGE ligand binding, increasing levels of soluble RAGE (sRAGE), and use of antioxidants. The above treatment aspect of AD is lacking. In conclusion, AGE-RAGE stress initiates, and Aβ, HMGB1, and S100 enhance the progression of AD. Reduction of levels of AGE and RAGE, elevation of sRAGE, and antioxidants would be beneficial therapeutic modalities in the prevention, regression, and slowing of progression of AD.

• Authors: Kailash Prasad
• Journal: Molecular and cellular biochemistry (Mol Cell Biochem) Vol. 459 Issue 1-2 Pg. 95-112 (Sep 2019) ISSN: 1573-4919 [Electronic] Netherlands
• PMID: 31079281 (Publication Type: Journal Article, Review)

Chemical References

• AGER protein, human
• Amyloid beta-Peptides
• Glycation End Products, Advanced
• HMGB1 Protein
• HMGB1 protein, human
• Reactive Oxygen Species
• Receptor for Advanced Glycation End Products
• S100 Proteins

Topics

• Alzheimer Disease (metabolism, pathology)
• Amyloid beta-Peptides (metabolism)
• Brain (metabolism, pathology)
• Glycation End Products, Advanced (metabolism)
• HMGB1 Protein (metabolism)
• Humans
• Oxidative Stress
• Reactive Oxygen Species (metabolism)
• Receptor for Advanced Glycation End Products (metabolism)
• S100 Proteins (metabolism)